DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715- ...

Conference Call Scheduled for August 5th at 8:30 AM ETNEWBURYPORT, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced the Company plans to report financial results for the second quarter ended June 30, 2025 on August 4, 2025 after the market close. The Company will hold a conference call to discuss results the following day, August 5th, at 8:30 ...

Life Time's L•AI•C generates personalized workouts, nutrition and supplement recommendations and recovery tips with decades of health and wellness content CHANHASSEN, Minn., July 29, 2025 /PRNewswire/ -- Not sure what kind of upper body workout to do today? Or which supplements you should start with? Just ask L•AI•C, Life Time's (NYSE: LTH) AI-powered healthy way of life companion. Now available to everyone through the complimentary Life Time app, L•AI•C (pronounced "lay-see") delivers instant, science-back ...

As Q2 earnings season rolls on, some of the world’s most influential tech and infrastructure companies have delivered strong results—but what’s catching Wall Street’s attention isn’t just the numbers, it’s the upgraded outlooks and rising price targets. In particular, three stocks—each deeply involved in the growth of artificial intelligence—have seen analysts sharply raise their expectations. While all three are in or nearing mega-cap territory (market caps of $200 billion or more), their post-earnings sha ...

Company Overview - Axogen, Inc. is a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function [1] - The company focuses specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [2] - Axogen's products address the needs of patients suffering from traumatic injuries or surgical procedures that impact peripheral nerve function [2] Product Portfolio - Axogen offers a comprehensive portfolio of products for peripheral nerve repair, including: - Avance Nerve Graft®, a biologically active processed human nerve allograft for bridging severed peripheral nerves [2] - Axoguard Nerve Connector®, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves [2] - Axoguard Nerve Protector®, a product used to wrap and protect damaged peripheral nerves [2] - Axoguard HA+ Nerve Protector™, designed to enhance nerve gliding and provide protection for peripheral nerve injuries [2] - Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft for tissue protection during repair [2] - Axoguard Nerve Cap®, used to protect a peripheral nerve end and reduce the development of symptomatic neuroma [2] Market Presence - Axogen's products are available in multiple markets, including the United States, Canada, the United Kingdom, South Korea, and several European and international markets [2] - The company plays a vital role in addressing diverse patient needs in peripheral nerve repair across various applications and surgical specialties [2]

SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix’s revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to su ...

Core Viewpoint - DBV Technologies reported its financial results for the second quarter and half-year of 2025, highlighting a net loss and changes in operating income and expenses, while also discussing its ongoing development of the Viaskin Peanut patch for food allergies [1][19]. Financial Highlights - The interim condensed consolidated financial statements were prepared in accordance with U.S. GAAP and IFRS [2]. - Operating income for the six months ended June 30, 2025, was $2.2 million, a decrease from $2.6 million in the same period of 2024, primarily due to a lower French Research Tax Credit entitlement [3][4]. - Operating expenses increased to $69.9 million for the six months ended June 30, 2025, compared to $65.0 million for the same period in 2024, driven mainly by the launch of the COMFORT Toddlers supplemental safety study [5][6]. Net Loss - The company recorded a net loss of $69.0 million for the six months ended June 30, 2025, compared to a net loss of $60.5 million for the same period in 2024. The net loss per share was $(0.58) for the first half of 2025, compared to $(0.63) for the same period in 2024 [7][9]. Cash Position - Cash and cash equivalents amounted to $103.2 million as of June 30, 2025, a significant increase from $32.5 million as of December 31, 2024, reflecting a net increase of $70.7 million [10][14]. - The company announced a financing of up to $306.9 million to advance the Viaskin Peanut patch, with gross proceeds of $125.5 million received on April 7, 2025 [11][12]. Assets and Liabilities - As of June 30, 2025, total assets were $143.4 million, with liabilities of $57.2 million, resulting in shareholders' equity of $86.2 million [16].

Core Viewpoint - Viasat, Inc. will release its first quarter fiscal year 2026 financial results on August 5, 2025, after market close, and will host a conference call and webcast on the same day [1][2]. Company Overview - Viasat is a global communications company with a mission to connect everyone and everything in the world, operating in 24 countries [3]. - The company aims to develop a global communications network that provides high-quality, reliable, secure, affordable, and fast connections, impacting lives positively [3]. - In May 2023, Viasat completed the acquisition of Inmarsat, enhancing its capabilities and resources [3].

PORTLAND, Ore., July 29, 2025 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative video and display processing solutions, will release its second quarter 2025 financial results on Tuesday, August 12, 2025, after market close. Todd DeBonis, President and CEO, and Haley Aman, CFO, will host a conference call at 2:00 p.m. Pacific Time to discuss the Company's financial results.Analysts and investors are invited to join the Company's conference call using the following information: ...

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conf ...